Thinly traded nano cap Caladrius Biosciences (NASDAQ:CLBS) is up 8% premarket on light volume on the heels of its announcement that the European Medicines Agency (EMA) has granted Advanced Therapy Medicinal Product (ATMP) status for cell therapy candidate CLBS12 for the potential treatment of critical limb ischemia (low blood flow to the lower extremities due to severely blockage of arteries).
Benefits of ATMP status include more intensive EMA guidance on development and fee reductions for regulatory advice.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.